Cell Source to Present at the LD Micro Main Event
LOS ANGELES, CA -- (Marketwired) -- 11/27/15 -- Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced that it will be presenting at the 8th annual LD Micro Main Event on Thursday, December 3rd at 4PM PST. Itamar Shimrat (CEO of Cell Source) will be giving the presentation and meeting with investors.
The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 210 companies in the small / micro-cap space.
About Cell Source, Inc.
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy
Cell Source will be presenting its expanded leadership team to include leading experts from Harvard University, Stanford University, University of Oxford, Mt. Sinai Medical and University Hospital Wurzburg.
Cell Source will describe its new patent applications aimed at enabling other cell therapy technologies (e.g., CAR-T) to use third party (allogeneic) cells and thus attain mass commercial viability by making them into "drug like" off-the-shelf products.
The company will reference first-in-human initial success in treating a patient with advanced cancer as well as its program to selectively pursue JV Pharma Collaborations where Veto Cell technology can significantly enhance the efficacy of cell therapy treatments for a variety of indications.
For more information go to www.cell-source.com
About LD Micro
LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on March 13, 2015. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
INVESTOR, MEDIA & GENERAL CORPORATE CONTACT:
Phone: +1 (646) 612-7554
Toll Free: +1 (888)-315-4650
Source: Cell Source, Inc.